AU4009899A - Molecules targeting cd40 and tumor cells - Google Patents

Molecules targeting cd40 and tumor cells

Info

Publication number
AU4009899A
AU4009899A AU40098/99A AU4009899A AU4009899A AU 4009899 A AU4009899 A AU 4009899A AU 40098/99 A AU40098/99 A AU 40098/99A AU 4009899 A AU4009899 A AU 4009899A AU 4009899 A AU4009899 A AU 4009899A
Authority
AU
Australia
Prior art keywords
tumor cells
molecules targeting
targeting
molecules
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40098/99A
Inventor
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU4009899A publication Critical patent/AU4009899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU40098/99A 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells Abandoned AU4009899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8662398P 1998-05-23 1998-05-23
US60086623 1998-05-23
PCT/US1999/011421 WO1999061057A2 (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Publications (1)

Publication Number Publication Date
AU4009899A true AU4009899A (en) 1999-12-13

Family

ID=22199807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40098/99A Abandoned AU4009899A (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Country Status (2)

Country Link
AU (1) AU4009899A (en)
WO (1) WO1999061057A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108001A (en) * 2000-02-01 2004-01-06 Tanox Inc CD-40-linked apc activator molecules
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
CN103429737B (en) 2010-11-30 2020-07-14 中外制药株式会社 Cytotoxic induction therapeutic agent
TWI726842B (en) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 Immune activation antigen binding molecule
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
CN109475603B (en) 2016-06-20 2023-06-13 科马布有限公司 anti-PD-L1 antibodies
JP7311425B2 (en) 2017-11-08 2023-07-19 協和キリン株式会社 Bispecific antibodies that bind to CD40 and EpCAM
EP3898681A2 (en) * 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
JPWO2020230901A1 (en) 2019-05-15 2020-11-19
KR20220008820A (en) 2019-05-15 2022-01-21 쿄와 기린 가부시키가이샤 Bispecific antibody that binds to CD40 and FAP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333807T2 (en) * 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR

Also Published As

Publication number Publication date
WO1999061057A3 (en) 2000-04-06
WO1999061057A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU3560399A (en) Tumor associated nucleic acids and uses therefor
AU4831399A (en) Leafy cotyledon1 genes and their uses
AU5279800A (en) Ion exchange resins and methods of making the same
AU3818300A (en) Treating hair by targeting enzymes
AU715620C (en) Therapeutic methods and uses
AU4009899A (en) Molecules targeting cd40 and tumor cells
AU4823599A (en) Prostate cancer-associated genes
AU1184399A (en) Therapeutic molecules
AU5874798A (en) Vaccination methods and molecules
AU7729498A (en) Methods and uses for transposon-based gene targeting
AU2238499A (en) Androgen-metabolic gene mutations and prostate cancer risk
AU6254799A (en) Anti-ige gene therapy
AU2587399A (en) Human transport-associated molecules
AU2506499A (en) Cea/nca-based differentiation cancer therapy
AU4629399A (en) Substituted piperazones and their therapeutic uses
AU5946999A (en) Tumour therapy and imaging
AU4860299A (en) (zap-3) tumor associated genes and their uses
AUPP263498A0 (en) Novel therapeutic molecules and uses therefor
AU5429699A (en) Drug targeting
AU3349997A (en) Reg gene expression in cancer tissue
AU2591099A (en) Human proteinase molecules
AU2044001A (en) Targeted bifunctional molecules and therapies based thereon
AU4050999A (en) Genes and enzymes
AU4552700A (en) Gene therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase